Advertisement
New Zealand markets closed

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NZD/USD

    0.5971
    +0.0021 (+0.35%)
     

  • NZD/EUR

    0.5558
    +0.0018 (+0.32%)
     

  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     

  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     

  • OIL

    83.92
    +0.35 (+0.42%)
     

  • GOLD

    2,352.30
    +9.80 (+0.42%)
     

  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     

  • DAX

    17,917.28
    -171.42 (-0.95%)
     

  • Hang Seng

    17,719.42
    +434.88 (+2.52%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • NZD/JPY

    93.2280
    +0.7320 (+0.79%)
     

Why Is Novo Nordisk Buying a Rare-Disease Candidate?

Keith Speights and Brian Orelli, PhD, The Motley Fool
·4-min read

Novo Nordisk (NYSE: NVO) recently announced that it's buying Prothena's (NASDAQ: PRTA) transthetyrin amyloidosis (ATTR) cardiomyopathy program for up to $1.2 billion. In this Motley Fool Live video recorded on July 14, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss why Novo, which is best known for its diabetes franchise, is buying a rare-disease drug candidate. There is a company, I don't know that we've talked about much, if at all in the past, Brian, Novo Nordisk.

Continue reading